81039-18-1

Upstream product

• 694-59-7 pyridine N-oxide 
• 78-67-1 2,2'-azobis(isobutyronitrile) 
• 78-82-0 Isobutyronitrile 
• 372-48-5 2-fluoropyridine 
• 100-70-9 2-Cyanopyridine 
• 109-04-6 2-bromo-pyridine 
• 2739-97-1 pyridine-2-acetonitrile 
• 74-88-4 methyl iodide 

Downstream Products

• 199296-39-4 2-methyl-2-(pyridin-2-yl)propan-1-amine 

Relevant academic research and scientific papers

Design of an Electron-Withdrawing Benzonitrile Ligand for Ni-Catalyzed Cross-Coupling Involving Tertiary Nucleophiles

The design of new ligands for cross-coupling is essential for developing new catalytic reactions that access valuable products such as pharmaceuticals. In this report, we exploit the reactivity of nitrile-containing additives in Ni catalysis to design a benzonitrile-containing ligand for cross-coupling involving tertiary nucleophiles. Kinetic and Hammett studies are used to elucidate the role of the optimized ligand, which demonstrate that the benzonitrile moiety acts as an electron-acceptor to promote reductive elimination over β-hydride elimination and stabilize low-valent Ni. With these conditions, a protocol for decyanation-metalation and Ni-catalyzed arylation is conducted, enabling access to quaternary α-arylnitriles from disubstituted malononitriles.

Synthesis of Nitrile-Bearing Quaternary Centers by an Equilibrium-Driven Transnitrilation and Anion-Relay Strategy

The efficient preparation of nitrile-containing building blocks is of interest due to their utility as synthetic intermediates and their prevalence in pharmaceuticals. As a result, significant efforts have been made to develop methods to access these motifs which rely on safer and non-toxic sources of CN. Herein, we report that 2-methyl-2-phenylpropanenitrile is an efficient, non-toxic, electrophilic CN source for the synthesis of nitrile-bearing quaternary centers by a thermodynamic transnitrilation and anion-relay strategy. This one-pot process leads to nitrile products resulting from the gem-difunctionalization of alkyl lithium reagents.

INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF

The invention provides a class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.

HETEROCYCLIC COMPOUND

The problem of the present invention is to provide a compound having a PDE2A inhibitory action, and useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Cyanide anion as a leaving group in nucleophilic aromatic substitution: Synthesis of quaternary centers at azine heterocycles

Nucleophilic aromatic substitution of 2- or 4-cyanoazines with the anions derived from aliphatic α,α-disubstituted esters and nitriles leads to displacement of the cyanide function. Enabling cyanides to be used as highly active leaving groups in SNAr reactions provides additional flexibility in starting materials for synthesis. We show that, in many cases, the cyanide leaving group is displaced preferentially in the presence of halogens. The resulting heteroaryl iodides, bromides, and chlorides subsequently can be used as handles for further chemical diversification.

FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE

Furanopyridine cannabinoid analog compounds of the formula (I) are disclosed. The compounds are useful to modify the activity of CB 1 and CB2 receptors and treat conditions mediated by these receptors.

FURANOPYRIMIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE

Furanopyrimidine cannabinoid analog compounds of the formula I are disclosed. The compounds are useful to modify the activity of CB 1 and CB2 receptors and treat conditions mediated by these receptors.

Pyrimidine Classical Cannabinoid Compounds and Related Methods of Use

Disclosed are compounds of the formula I: wherein R1, R2, V, W, X, Y and Z can be as defined herein. The compounds can be used in the treatment of disorders mediated by the cannabinoid receptors.

Pyrimidine Non-Classical Cannabinoid Compounds and Related Methods of Use

Disclosed are compounds of the formula I: wherein R1, R2, V, W, X, Y and Z can be as defined herein. The compounds can be used in the treatment of disorders mediated by the cannabinoid receptors.

Pyridine Classical Cannabinoid Compounds and Related Methods of Use

Disclosed are compounds of the formula I: wherein R1, R2, V, W, X, Y and Z can be as defined herein. The compounds can be used in the treatment of disorders mediated by the cannabinoid receptors.